Oppenheimer reiterated their outperform rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the company. Citigroup began coverage on Catalyst […]

Related Keywords

United States , America , Brian Elsbernd , Parkside Financial Bank , News Ratings For Catalyst Pharmaceuticals Daily , Covestor Ltd , Catalyst Pharmaceuticals , Securities Exchange Commission , Catalyst Pharmaceuticals Stock Performance , Catalyst Pharmaceuticals Inc , Citigroup , Cantor Fitzgerald , Analyst Recommendations For Catalyst Pharmaceuticals , Advisory Services Network , Visionpoint Advisory Group , Free Report , Get Free Report , Exchange Commission , Services Network , Financial Bank , Catalyst Pharmaceuticals Daily ,